![]() |
Name |
Altiloxin E
|
Molecular Formula | C15H24O4 | |
IUPAC Name* |
2,6-dihydroxy-2,5,5,8a-tetramethyl-3,6,7,8-tetrahydro-1H-naphthalene-1-carboxylicacid
|
|
SMILES |
CC1(O)CC=C2C(C)(C)C(O)CCC2(C)C1C(=O)O
|
|
InChI |
InChI=1S/C15H24O4/c1-13(2)9-5-8-15(4,19)11(12(17)18)14(9,3)7-6-10(13)16/h5,10-11,16,19H,6-8H2,1-4H3,(H,17,18)/t10-,11+,14-,15+/m0/s1
|
|
InChIKey |
KCRVPPZUVWUMHE-IDTSFGKNSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 268.35 | ALogp: | 2.0 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 77.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.639 |
Caco-2 Permeability: | -5.221 | MDCK Permeability: | 0.00002060 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.008 |
Human Intestinal Absorption (HIA): | 0.032 | 20% Bioavailability (F20%): | 0.033 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.406 | Plasma Protein Binding (PPB): | 52.74% |
Volume Distribution (VD): | 0.494 | Fu: | 43.78% |
CYP1A2-inhibitor: | 0.007 | CYP1A2-substrate: | 0.499 |
CYP2C19-inhibitor: | 0.013 | CYP2C19-substrate: | 0.652 |
CYP2C9-inhibitor: | 0.02 | CYP2C9-substrate: | 0.823 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.142 |
CYP3A4-inhibitor: | 0.026 | CYP3A4-substrate: | 0.052 |
Clearance (CL): | 3.446 | Half-life (T1/2): | 0.292 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.116 |
Drug-inuced Liver Injury (DILI): | 0.036 | AMES Toxicity: | 0.037 |
Rat Oral Acute Toxicity: | 0.08 | Maximum Recommended Daily Dose: | 0.032 |
Skin Sensitization: | 0.079 | Carcinogencity: | 0.182 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.244 |
Respiratory Toxicity: | 0.965 |